Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Early Phase I Study of A Window of Opportunity Strategy for Targeted Pathway Inhibition in Patients With Pancreatic Ductal Adenocarcinoma

Summary

The purpose of this early phase I study is to determine the safety and efficacy of cobimetinib, olaparib, temuterkib, or onvansertib works in patients with pancreatic cancer.

General Information

NCT#: NCT04005690
Study ID: STUDY00019211
Trial Phase: Phase I

Trial Sponsor: Oregon Health & Science University Knight Cancer Institute
Therapies Used in This Trial: Olaparib, Cobimetinib, Onvansertib, temuterkib

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search